Search Results (4)

Gas sensors provide versatile opportunities for detecting volatile organic compounds (VOCs) such as acetone, methanol, ethanol, propanol, isoprene, and aldehydes in exhaled breath (EB) associated with COVID-19 respiratory infections. These VOCs provide valuable information about metabolic markers linked with COVID-19. They have opened opportunities to develop sensors for COVID-19 screening based on breath analysis. These sensors have the potential to provide the rapid detection of viruses in healthcare settings. RT-PCR, as a conventionally adopted diagnostic method, has a detection limit around 10–100 RNA copies/mL, with an accuracy of around 95%. Gas sensors have demonstrated VOC detection limits at the ppm level in COVID-19 EB and have displayed a sensitivity and specificity of 98.2% and 74.3%, respectively. Multiple gas sensors combined with machine learning algorithms have the potential to enhance the specificity of VOC detection. In addition to having an accuracy similar to that of the PCR method, the VOC-based diagnosis of COVID-19 offers unique advantages in terms of non-invasive and rapid detection. This review provides an overview of state-of-the-art gas sensors developed for COVID-19 detection. Despite there being significant developments in this field, there are certain challenges that still need to be addressed—these include the impact of environmental factors, the specificity of detection, the sensing range, and precision limitations, leading to accuracy issues. Despite these existing challenges, the integration of gas sensors with machine learning methods can enhance the accuracy of the detection of COVID-19. Future research directions are proposed to validate and standardize the application of gas sensors for COVID-19 in clinical settings. Full article

Exhaled breath (EB) contains numerous volatile organic compounds (VOCs) that can reflect pathological metabolic processes, making breath analysis a promising non-invasive diagnostic approach. In particular, volatile aldehydes and ketones have been identified as disease biomarkers in EB. Gas sensors are expected to play a crucial role in the diagnosis of numerous diseases at an early stage. Among the various available approaches, sensors stand out as especially attractive tools for diagnosing diseases such as lung cancer (LC) and diabetes, due to their affordability and operational simplicity. There is an urgent need in the field of disease detection for the development of affordable, non-invasive, and user-friendly sensors capable of detecting various biomarkers. Devices of the new generation should also demonstrate high repeatability of measurements and extended operational stability of the employed sensors. Due to these demands, the past few years have seen significant advancements in the development and implementation of electronic noses (ENs), which are composed of an array of sensors for the determination of VOCs present in EB. To meet these requirements, the development and integration of advanced receptor coatings on sensor transducers is essential. These coatings include nanostructured materials, molecularly imprinted polymers, and bioreceptors, which collectively enhance selectivity, sensitivity, and operational stability. However, reliable biomarker detection in point-of-care (PoC) mode remains a significant challenge, constrained by several factors. This review provides a comprehensive and critical evaluation of recent studies demonstrating that the detection of VOCs using gas sensor platforms enables disease detection and can be implemented in PoC mode. Full article

Breast cancer (BC) is the most commonly occurring cancer in women and one of the leading causes of cancer death in women worldwide. BC mortality is related to early tumor detection, highlighting the importance of early detection methods. This work aims to develop a robust, accurate and highly reliable, non-invasive, low-cost screening method for early detection of BC in routine screening using exhaled breath (EB) analysis. For this, exhaled breath samples were collected from 267 women: 131 breast cancer patients and 136 healthy women. After collection, the samples were measured using a commercially available electronic nose. The signals obtained for each sample were first processed and then went through a feature extraction step. An SVM model was then optimized with respect to the accuracy matrix using a validation set by applying a Monte Carlo cross-validation with 100 iterations, with each iteration containing 20% of the data. The validation set results were 80, 94, 88, and 95% for recall, precision, accuracy, and specificity, correspondingly. Once model optimization had concluded, 22 unknown samples were analyzed by the model, and an accuracy, precision, and specificity of 91% was achieved. Full article

Currently, a small number of diseases, particularly cardiovascular (CVDs), oncologic (ODs), neurodegenerative (NDDs), chronic respiratory diseases, as well as diabetes, form a severe burden to most of the countries worldwide. Hence, there is an urgent need for development of efficient diagnostic tools, particularly those enabling reliable detection of diseases, at their early stages, preferably using non-invasive approaches. Breath analysis is a non-invasive approach relying only on the characterisation of volatile composition of the exhaled breath (EB) that in turn reflects the volatile composition of the bloodstream and airways and therefore the status and condition of the whole organism metabolism. Advanced sampling procedures (solid-phase and needle traps microextraction) coupled with modern analytical technologies (proton transfer reaction mass spectrometry, selected ion flow tube mass spectrometry, ion mobility spectrometry, e-noses, etc.) allow the characterisation of EB composition to an unprecedented level. However, a key challenge in EB analysis is the proper statistical analysis and interpretation of the large and heterogeneous datasets obtained from EB research. There is no standard statistical framework/protocol yet available in literature that can be used for EB data analysis towards discovery of biomarkers for use in a typical clinical setup. Nevertheless, EB analysis has immense potential towards development of biomarkers for the early disease diagnosis of diseases. Full article